Holding(s) in Company

RNS Number : 4832N
Advanced Medical Solutions Grp PLC
18 February 2009



For immediate release

  Wednesday 18 February 2009

Advanced Medical Solutions Group plc 

(“AMS” or “the Company”)

Holding in Company

Advanced Medical Solutions Group plc (the “Company”) was notified on 17 February 2009 that Cavendish Asset Management Ltd (“Cavendish Asset Management”) disposed of 1,125,000 ordinary shares of 5 pence each in the Company (“Ordinary Shares”) on 13 February and 2,769,000 Ordinary Shares on 16 February, at 33.00 pence per share. Following these transactions, discretionary clients of Cavendish Asset Management are interested in 3,905,000 Ordinary Shares.

In addition, Cavendish Opportunities Fund is interested in 1,000,000 Ordinary Shares and the Cavendish AIM Fund is interested in 150,000 Ordinary Shares. In total Cavendish Asset Management is interested in 5,055,000 Ordinary Shares equaling 3.53 per cent. of the Company’s issued share capital. 

-ENDS- 

For further information, please contact:

Advanced Medical Solutions Group plcDon Evans, Chief Executive Officer

Mary Tavener, Finance Director

www.admedsol.com

Tel: +44 (0) 1606 545508

Buchanan Communications

Mark Court, Mary-Jane Johnson, Stasa Filiplic

Tel: +44 (0) 20 7466 5000

Teathers

Shaun Dobson / Claes Spang

Tel: +44 (0) 20 7426 9000

Notes to Editors:

Advanced Medical Solutions is a leading company in the development and manufacture of products for the $15 billion global woundcare market.

Founded in 1991 and quoted on AIM, Advanced Medical Solutions is focused on the design, development and manufacture of innovative and technologically advanced woundcare products.

In-house natural and synthetic polymer technology is used to provide advanced wound dressings based on the moist healing principle. AMS’ resources ensure a unique position as a vertically integrated ‘one stop shop’ to provide all categories of moist wound healing products. The Company has the capability to move a product from design and development through to production and delivery for distribution and sale into customer markets.

The acquisition of 49.4% of Corpura BV in May 2008 strengthened AMS’ position in hydrophilic polyurethane foam – the largest and fastest growing segment of the advanced woundcare market

AMS’ technology in cyanoacrylate based tissue adhesives is used either for the closure of small cuts and trauma wounds through to large surgical incisions, or for protecting or sealing skin to prevent breakdown or infection. 

AMS’ products currently serve the majority of the key global markets sold either direct or through strategic partners or distributors.


This information is provided by RNS
The company news service from the London Stock Exchange